Hepion Pharmaceuticals In...

0.80
-0.03 (-3.50%)
At close: Mar 21, 2025, 3:59 PM
0.78
-2.10%
After-hours: Mar 21, 2025, 07:03 PM EDT
-3.50%
Bid 0.76
Market Cap 863.03K
Revenue (ttm) 3.47K
Net Income (ttm) -717.71K
EPS (ttm) -220
PE Ratio (ttm) n/a
Forward PE -0.02
Analyst n/a
Ask 0.79
Volume 2,731,559
Avg. Volume (20D) 876,533
Open 0.78
Previous Close 0.83
Day's Range 0.72 - 0.83
52-Week Range 0.67 - 145.00
Beta 1.63

About HEPA

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH...

Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2014
Employees 22
Stock Exchange NASDAQ
Ticker Symbol HEPA
Full Company Profile
1 week ago
-39.15%
Hepion Pharmaceuticals shares are trading lower af... Unlock content with Pro Subscription
1 month ago
-58.05%
Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.